The FDA's alignment on a potential path forward is a positive but non-binding step. Resubmission and eventual approval remain uncertain. Monitor for the Q3 2026 update and any interim data releases for clearer catalysts.
Price Chart
Executive Summary
Atara reported that after a Type A meeting with the FDA, the agency agreed that a single-arm study with an appropriate historical control could support resubmission of the tabelecleucel (tab-cel) BLA. Partner Pierre Fabre plans to submit an updated dataset from the ALLELE study with additional patients and longer follow-up. The company expects a further regulatory update in Q3 2026.
Key Facts
- FDA agreed a single-arm study with historical control could support tab-cel BLA resubmission.
- Pierre Fabre intends to submit updated ALLELE study data with more patients and longer follow-up.
- Next regulatory update expected in Q3 2026.
- Tab-cel BLA received a Complete Response Letter on January 9, 2026.
Financial Impact
No financial figures disclosed; potential upside if resubmission leads to approval, but timeline and probability uncertain.
Risk Factors
- Resubmission may not fully address CRL deficiencies.
- Partner Pierre Fabre controls the BLA and resubmission process.
- No guarantee of eventual FDA approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-210413 |
| Document: atra-ex99_1.htm | 0001193125-26-210413 |
| Document: 0001193125-26-210413-index-headers.html | 0001193125-26-210413 |
| Document: 0001193125-26-210413-index.html | 0001193125-26-210413 |
| Document: 0001193125-26-210413.txt | 0001193125-26-210413 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 26, 2026 14w ago | 8-K | $11.17 $8.93 | ▼ −20.05% | ▼ −24.44% | $9.48 (−15.13%) |
Jun 15, 2026 15w ago | 3 | $9.62 $9.89 | ▲ +2.81% | ▲ +1.81% | $9.48 (−1.46%) |
May 7, 2026 21w ago | 8-K | $9.93 $8.55 | ▼ −13.90% | ▼ −17.73% | $9.48 (−4.53%) |
May 7, 2026 21w ago | Insider Cluster | $9.93 $8.55 | ▼ −13.90% | ▼ −17.73% | $9.48 (−4.53%) |
Apr 24, 2026 23w ago | DEFA14A | $4.99 $8.13 | ▲ +62.83% | ▲ +58.05% | $9.48 (+89.98%) |
Mar 17, 2026 28w ago | S-3 | $5.00 $10.46 | ▲ +109.20% | ▲ +97.67% | $9.48 (+89.60%) |
Mar 12, 2026 29w ago | 8-K | $6.90 $9.92 | ▲ +43.77% | ▲ +33.07% | $9.48 (+37.39%) |
Mar 3, 2026 30w ago | 8-K | $5.42 $10.54 | ▲ +94.46% | ▲ +84.15% | $9.48 (+74.91%) |
Mar 2, 2026 30w ago | Insider Cluster | $4.91 $9.61 | ▲ +95.72% | ▲ +86.40% | $9.48 (+93.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access